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Abstract  
Molecular similarity is an elusive but core ‘unsupervised’ cheminformatics concept, yet different 
‘fingerprint’ encodings of molecular structures return very different similarity values even when 
using the same similarity metric. Each encoding may be of value when applied to other problems 
with objective or target functions, implying that a priori none is ‘better’ than the others, nor than 
encoding-free metrics such as maximum common substructure (MCSS). We here introduce a 
novel approach to molecular similarity, in the form of a variational autoencoder (VAE). This learns 
the joint distribution p(z|x) where z is a latent vector and x are the (same) input/output data. It takes 
the form of a ‘bowtie’-shaped artificial neural network. In the middle is a ‘bottleneck layer’ or latent 
vector in which inputs are transformed into, and represented as, a vector of numbers (encoding), 
with a reverse process (decoding) seeking to return the SMILES string that was the input. We train 
a VAE on over 6 million druglike molecules and natural products (including over one million in the 
final holdout set). The VAE vector distances provide a rapid and novel metric for molecular 
similarity that is both easily and rapidly calculated. We describe the method and its application to a 
typical similarity problem in cheminformatics. 
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Introduction 
The concept of molecular similarity lies at the core of cheminformatics [1-3]. It implies that 
molecules of ‘similar’ structure tend to have similar properties. Thus, a typical question can be 
formulated as follows: “given a molecule of interest M, possibly showing some kind of chemical 
activity, find me the nearest 50 molecules from a potentially huge online collection to purchase that 
are most similar to M so I can assess their behaviour in a relevant quantitative-structure-activity 
(QSAR) analysis”.   
The most common strategies for assessing molecular similarity involve encoding the molecule as a 
vector of numbers, such that the vectors encoding two molecules may be compared according to 
their Euclidean or other distance. In the case of binary strings the Jaccard or Tanimoto similarity 
(TS) is commonly used [4] as it is a metric (between zero and one). One means for obtaining such 
a vector for a molecule is to calculate from the structure (or measure) various properties of the 
molecule (‘descriptors’ [5-7]), such as clogP or total polar surface area, and then to concatenate 
them. However, a more common strategy for obtaining the encoding vector of numbers is simply to 
use structural features directly and to encode them as so-called molecular fingerprints [8-17]. Well-
known examples include MACCS [18], atom pairs [19], torsion [20], extended connectivity [21], 
functional class [22], circular [23], and so on. The similarities so encoded can also then be 
compared as their Jaccard or Tanimoto similarities. Sometimes a ‘difference’ or ‘distance’ is 
discussed and formulated as 1-TS (a true metric). An excellent and widely used framework for 
doing all of this is RDKit (www.rdkit.org/) [24], that presently contains nine methods for producing 
molecular fingerprints. 
The problem comes from the fact that the ‘most similar’ molecules to a target molecule often differ 
wildly both as judged by their structures observable by eye and quantitatively in terms of the value 
of the TS of the different fingerprints [25]. As a very small and simple dataset, we take the set of 
molecules observed by Dickens and colleagues [26] to inhibit the transporter-mediated uptake of 
the second-generation atypical antipsychotic drug clozapine. These are Olanzapine, 
Chlorpromazine, Quetiapine, Prazosin, Lamotrigine, Indatraline, Verapamil and Rhein. Of the FDA 
approved drugs, we assessed the top 50 drugs in terms of their structural similarity to clozapine 
using the nine RDKit encodings, with the results shown in Table 1 and Fig 1. Only the first four of 
these are even within the top 50 for any encoding, and only olanzapine appears for each of them. 
By contrast, the most potent inhibitor is prazosin (which is not even wholly of the same drug class, 
being both a treatment for anxiety and a high-blood-pressure-lowering agent); however, it appears 
in the top 50 in only one encoding (torsion) and then with a Tanimoto similarity of just 0.37. This 
said, visual inspection of their ‘Kekularised’ structures does show a substantial common 
substructure between prazosin and clozapine (marked in Fig 1). It is clear that the similarities as 
judged by standard fingerprint encodings are highly variable, and are prone to both false negatives 
and false positives when it comes to attacking the question as set down above. What we need is a 
different kind of strategy. 
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 Figure 1. Tanimoto similarities of various molecules to clozapine using the Torsion encoding from 
RDKit. 
 
 
Table 1. Tanimoto similarity to clozapine using nine different RDKit encodings and their ability to 
inhibit clozapine transport (data extracted from [26]). A shaded cell means that the molecule was 
not judged to be in the ‘top 50’ using that encoding. 
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Figure 2. Two kinds of neural architecture. A. A classical multilayer perceptron representing a 
supervised learning system in which molecules encoded as SMILES strings can be used as paired 
inputs with outputs of interest (whether a classification or a regression). The trained model may 
then be interrogated with further molecules and the output ascertained. B. A variational 
autoencoder, is a supervised means of fitting distributions of discrete models in a way that 
reconstructs them via a vector in a latent space. C. The VAE architecture used in the present work. 
The typical structure of a QSAR type of problem is given in Fig 2A, where a series of molecules 
represented as SMILES strings [27] are encoded as molecular fingerprints and used to learn a 
nonlinear mapping to produce an output in the form of a classification or regression estimation. The 
architecture of this is implicitly in the form of a multilayer perceptron (a classical neural network 
[28-31]), in which weights are modified (‘trained’) to provide a mapping from input SMILES to a 
numerical output. Our fundamental problem stems from the fact that these types of encoding are 
one-way: The SMILES string can generate the molecular fingerprint but the molecular fingerprint 
cannot generate the SMILES. Put another way, it is the transition from a world of discrete objects 
(here molecules) with categorical representations (here SMILES strings) to one of a continuous 
representation (vectors of weights) that is seemingly irreversible in this representation. One key 
element is the means by which we can go from a non-numerical representation (such as SMILES 
or similar [32]) to a numerical representation or ‘embedding’ (that, as we shall see, is typically 
constituted by vectors of numbers in the nodes and weights of multilayer neural networks) [33-38]). 
Deep learning has also been used for the encoding step of 2D chemical structures [39; 40].  
More recently, it was recognised that various kinds of architectures could in fact permit the reversal 
of this numerical encoding so as to return a molecule (or its SMILES string encoding a unique 
structure). These are known as generative methods [41-50], and at heart their aim to generate a 
suitable and computationally useful representation [51] of the input data. It is common (but cf. [52; 
53]) to contrast two main flavours: generative adversarial networks [54-61] and (especially 
variational) autoencoders (VAEs) [41; 42; 62-71]. We focus here on the latter, illustrated in Fig 2B.  
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VAEs are latent-variable generative models that define a joint density pθ(x,z) between some 
observed data x ∈ ℝdx and unobserved or latent variables z ∈ ℝdz [72], given some model 
parameters θ. They use a variational posterior (also referred to as an encoder), qϕ(z | x), to 
construct the latent variables with variational parameters ϕ, and a combination of p(z) and p(x|z) to 
create a decoder that has the opposite effect. Learning the posterior directly is computationally 
intractable, so the generic deep learning strategy is to train a neural network to approximate it. The 
original ‘error’ backpropagated was based on the Kullback-Leibler (KL) divergence between the 
desired (log likelihood reconstruction error) and the predicted output distributions [62]. A very great 
many variants of both architectures and divergence metrics have been proposed since then (not all 
discernibly better [73]), and it is a very active field (e.g. [58; 59; 74; 75]). Since tuning is necessarily 
domain-specific [76], and most work is in the processing of images and natural languages rather 
than in molecules, we merely mention a couple, such as transformers (e.g. [77; 78]) and others 
(e.g. [79; 80]). Crucial to such autoencoders (that can also be used for data visualisation [81]) is 
the concept of a bottleneck layer, that as a series of nodes of lower dimensionality than its 
predecessors or successors, serves to extract or represent [51] the crucial features of the input 
molecules that are nonetheless sufficient to admit their reconstruction. Indeed, such strategies are 
sometimes referred to as representational learning. 
A higher-level version of the above might state that a good variational autoencoder will project a 
set of discrete molecules into a continuous latent space represented for any given molecule by the 
vector representing the values of the outputs of the nodes in the bottleneck layer when it (or its 
SMILES representation) is applied to the encoder as an input. As with the commonest neural net 
training system (but cf. [82-86]), we use backpropagation to update the network so as to minimise 
the difference between the predicted and the desired output, subject to any other constraints that 
we may apply. We also recognise the importance of various forms of regularisation, that are all 
designed to prevent overfitting [49; 87-90]. 
Because the outputs of the nodes in the bottleneck layer both (i) encode the molecule of interest 
and (ii) effectively represent where molecules are in the chemical space on which they have been 
trained, a simple metric of similarity between two molecules is clearly the Euclidean or other 
comparable distance (e.g. cosine distance) between these vectors. This thus provides for a novel 
type of similarity encoding, that in a sense relates the whole chemical space on which the system 
has been trained and that we suspect may be of general utility. We might refer to this encoding as 
the ‘essence of molecules’ (EM) encoding, but here refer to it as VAE-Sim.  
Thus, the purpose of the present article is to describe our own implementation of a simple VAE and 
its use in molecular similarity measurements as applied, in particular, to the set of drugs, 
metabolites and natural products that we have been using previously [25; 91-96] as our benchmark 
for similarity metrics.  
Methods 
We considered and tested grammar-based and junction-tree methods such as those used by 
Kajino [35], that exploited some of the ideas developed by Dai [97], Kusner [98] and by Jin and 
their colleagues [34]. However, our preferred method as described here used one-hot encoding as 
set out by Gómez-Bombarelli and colleagues [69]. We varied the number of molecules in the 
training process from ca 250,000 to over 6 million; the large number of possible hyperparameters 
would have led to a combinatorial explosion, so exhaustive search was (and is) not possible. The 
final architecture used here (shown in Fig 2C) required 6 days’ training on a 1-GPU machine. It 
involved a CNN encoder with the following layers (Fig 2C): convolution (1D): size (in-
248=SMILES string length, 40 possible unique SMILES characters, out-9, kernel_size=9), ReLU, 
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convolution (1D): size (in-9, out-9, kernel_size=9) ReLU,  convolution (1D): size (in-9, out-10, 
kernel_size=11) ReLU, Linear (fully connected): size(140, latent_dims=100) SeLU, with VAE 
mean- Linear (fully connected): size(140, latent_dims=100) and variance- Linear (fully connected): 
size(140, latent_dims=100). For the decoder we used a Reparametarization (combined mean and 
sigma together) such that the output will be the same as the latent dimension (100 in our case), 
Linear (fully connected): size(latent_dims=100, latent_dims=100) SeLU, RNN-GRU (gated 
neural unit): size (hidden size=488, num_layers=3), Linear (fully connected): size(in-
488=hidden_gru_size, out-248=SMILES length) Softmax. For the loss we used binary cross-
entropy + KL-divergence. Neither dropout nor pooling were used. The optimiser was ADAM [99], 
the fixed learning rate 0.0001, parameters were initialised using the ‘Xavier uniform’ scheme [100], 
and a batch size of 128. This was implemented in Python using the Pytorch library 
(https://pytorch.org/). Most of the pre- and post-processing cheminformatics workflows were written 
in the KNIME environment (see [101]).  
Results 
Autoencoders that use SMILES as inputs can return three kinds of outputs: (i) the correct SMILES 
output mirroring the input and/or translating into the input molecular structure (referred to as 
‘perfect’), (ii) an incorrect output of a molecule different from the input but that is still legal SMILES 
(hence will return a valid molecule), referred to as ‘good’, and (iii) a molecule that is simply not 
legal SMILES. In practice, our VAE after training returned more than 95% valid SMILES in the test 
(holdout) set, so those that were invalid could simply be filtered out without significant loss of 
performance. Following training, each molecule (SMILES) could be associated with a normalised 
vector of 100 dimensions, and the Euclidean distance between them could be calculated.  
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As previously [25], we compared the similarities between all drugs and all metabolites using the 
datasets made available in [91]. We here focus on just the MACCS and Patterned encodings of 
RDKit, and compare them with the normalised Euclidean distances according to the latent vector 
obtained from the VAE. As before, we rank ordered each drug in terms of its closest similarity to 
any metabolite. First, Fig 3A (reading from right to left) shows the Tanimoto similarities for the 
Patterned and MACCS  fingerprints, as well as the VAE-Sim values as judged by two metrics. The 
first, labelled E-Sim (Eq 1), is the Euclidean similarity, based on the raw 100-dimensional hidden 
vectors, while the second, EU-Sim (Eq 2), used the Uniform Manifold Approximation and Projection 
(UMAP) dimension reduction algorithm [102; 103] based on the first two UMAP dimensions was 
used for purposes of visualisation; clearly, as with other encodings, they do not at all follow the 
same course, and one that may be modified according to the similarity measure used. Figures 3B 
and 3C show the ‘all-vs-all’ heatmaps for two of the encodings, indicating again that the VAE-Sim 
encoding falls away considerably more quickly, i.e. that similarities are judged in a certain sense 
more ‘locally’. 
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Figure 3. Top similarities between drugs and metabolites as judged by a fingerprint encoding 
(RDKit patterned) and our new VAE-Sim metric. A. Rank ordering. B. Heatmap for Tanimoto 
similarities using RDKit patterned encoding. C. Heatmap of Euclidean similarities E-Sim (Eq 1) for 
VAE-Sim in the 100-dimensional latent vector). D Heatmap of Euclidean similarities EU-Sim (Eq 2) 
for VAE-Sim in 2-dimensional UMAP space. 
 
Figure 4A shows the Patterned similarity for the ‘most similar’ metabolite for each drug (using TS) 
compared to that for VAE-Sim (using Euclidean distance), while Figure 4B shows the same for the 
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MACCS encoding. These again illustrate how the new encoding provides a quite different readout 
from the standard fingerprint encodings.   
 
 
Figure 4. Comparison of similarities between two RDKit fingerprint methods and VAE-Sim Using 
Tanimoto similarity for fingerprints and Euclidean d100 similarity for VAE-Sim. A. Patterned 
encoding. B. MACCS encoding. 
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Figure 5. Similarity of drugs to clozapine as judged by the VAE. A. Rank order of Euclidean 
similarity in 100 dimensions (E-Sim) vs 2 UMAP dimensions (EU-Sim) as in Figure 3. Some of the 
‘most similar’ drugs are labelled, as are some of those in Table 1. B. Structures of some of the 
drugs mentioned. 
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Finally, we used our new metrics to determine the similarity to clozapine of other drugs. Figure 5 
shows the two similarity scores based on VAE-Sim, calculated as in Figure 3. Gratifyingly, and 
while structural similarity is, in part, in the eye of the beholder, a variety of structurally and 
functionally related antipsychotic drugs such as loxapine, mirtazapine and quetiapine were indeed 
among the most similar to clozapine, while others not previous considered (such as the 
antihistamines ketotifen and alcaftadine and the anti-inflammatory COX inhibitor ketorolac) were 
also suggested as being similar, providing support for the orthogonal utility of the new VAE-Sim 
metric. However, the rather promiscuous nature of clozapine binding (e.g. [104; 105]), and that of 
many of the other drugs (e.g. [106-112]), mean that this is not the place to delve deeper.  
Discussion 
Molecular similarity is at the core of much of cheminformatics (e.g. [3; 8; 113-116]), but is an 
elusive concept. Our chief interest typically lies in supervised methods such as QSARs, where we 
use knowledge of paired structures and activities to form a model that allows us to select new 
structures with potentially desirable activities. Modern modelling methods such as feedforward 
artificial neural networks based on multilayer perceptrons are very powerful (and they can in fact fit 
any nonlinear function – the principle of “universal approximation” [117; 118]). Under these 
circumstances it is usually possible to learn a QSAR using any of the standard fingerprints. 
However, what we are focused on here is a purely unsupervised representation of the structures 
themselves (cf [37] which used substructures), and the question of which of these are the ‘most 
similar’ to a query molecule of interest. Such unsupervised methods may be taken to include any 
kinds of unsupervised clustering too (e.g. [119-123]). As with any kind of system of this type, the 
‘closeness’ is a function of the weighting of any individual features, and it is perhaps not surprising 
that the different fingerprint methods give vastly different similarities, even when judged by rank 
order (e.g. [25] and above). One similarity measure that is independent of any fingerprint encoding 
is represented by the maximum common substructure (MCSS). However, by definition, the MCSS 
uses only part of a molecule; it is also computationally demanding [93; 94], such that ‘all-against-
all’ comparisons such as those presented here are out of the question for large numbers of 
molecules.  
Here we have leveraged a new method that uses only the canonical SMILES encoding of the 
molecules themselves, leading to its representation as a 100-element vector. Simple Euclidean 
distances can be used to obtain a metric of similarity that unlike MCSS is rapidly calculated for any 
new molecule, even against the entire set of molecules used in the development of the latent 
space.  
In addition, unlike any of the other methods described, methods such as VAEs are generative: 
moving around in the latent space and applying the vector so created to the decoder allows for the 
generation of entirely new molecules (e.g. [41-45; 48; 50; 58; 60; 68; 69; 124]). This opens up a 
considerable area of chemical exploration, even in the absence of any knowledge of bioactivities.  
What determines the extent to which VAEs can generate novel examples?  
The ability of variational autoencoders to generalise is considered to be based on learning a 
certain ‘neighbourhood’ around each of the training examples [72; 125], seen as a manifold of 
lower dimensionality than the dimensionality of the input space [51]. Put another way, “the 
reconstruction obtained from an optimal decoder of a VAE is a convex combination of examples in 
the training data” [126]. On this basis, an effect of training set size on the improvement of 
generalisation (here defined simply as being able to return an accurate answer from a molecule not 
in the training set) is to be expected, and our ability to generalise (as judged by test set error) 
improved as the number of molecules increased up to a few million. However, although we did not 
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explore this, it is possible that our default architecture was simply too large for the smaller number 
of molecules, as excessive ‘capacity’ can cause a loss of generalisation ability [126]. This of course 
leaves open the details of the size and ‘closeness’ of that neighbourhood, how it varies with the 
encoding used (our original problem) and what features are used in practice to determine that 
neighbourhood. The network described here took nearly a week to train on a well-equipped GPU-
based machine, and exhaustive analysis of hyperparameters was not possible. Consequently, 
because an understanding of the importance of local density will vary as a function of the position 
and nature of the relevant chemical space, we are not going to pursue them here. What is 
important is (i) that we could indeed learn to navigate these chemical spaces, and (ii) that the VAE 
approach admits a straightforward and novel estimation of molecular similarity. 
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Legends to Figures 
Figure 1. Tanimoto similarities of various molecules to clozapine using the Torsion encoding from 
RDKit. 
Figure 2. Two kinds of neural architecture. A. A classical multilayer perceptron representing a 
supervised learning system in which molecules encoded as SMILES strings can be used as paired 
inputs with outputs of interest (whether a classification or a regression). The trained model may 
then be interrogated with further molecules and the output ascertained. B. A variational 
autoencoder, is a supervised means of fitting distributions of discrete models in a way that 
reconstructs them via a vector in a latent space. C. The VAE architecture used in the present work. 
Figure 3. Top similarities between drugs and metabolites as judged by a fingerprint encoding 
(RDKit patterned) and our new VAE-Sim metric. A. Rank ordering. B. Heatmap for Tanimoto 
similarities using RDKit patterned encoding. C. Heatmap of Euclidean similarities E-Sim (Eq 1) for 
VAE-Sim in the 100-dimensional latent vector). D Heatmap of Euclidean similarities EU-Sim (Eq 2) 
for VAE-Sim in 2-dimensional UMAP space. 
Figure 4. Comparison of similarities between two RDKit fingerprint methods and VAE-Sim Using 
Tanimoto similarity for fingerprints and Euclidean d100 similarity for VAE-Sim. A. Patterned 
encoding. B. MACCS encoding 
Figure 5. Similarity of drugs to clozapine as judged by the VAE. A. Rank order of Euclidean 
similarity in 100 dimensions (E-Sim) vs 2 UMAP dimensions (EU-Sim) as in Figure 3. Some of the 
‘most similar’ drugs are labelled, as are some of those in Table 1. B. Structures of some of the 
drugs mentioned. 
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